0.2452USD-1.13%Mkt Cap: —P/E: —1d ago
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value1.22M $
Revenue (TTM)95.00K $
Gross Profit-22.00K $
Net Income (TTM)-14.27M $
Revenue/Share0.0140 USD
Last Price0.2452 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees19
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS00901B1052
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.11
EV/Revenue12.88
P/S—
P/B0.90
EPS (TTM)-0.40
EPS (Forward)—
52W Range
0.236044% of range0.2567
52W High0.2567 USD
52W Low0.2360 USD
Profitability
Gross Margin-23.16%
Oper. Margin-13511.54%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-2382.30%
ROA-82.58%
Growth
Revenue Growth4.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-14.37M $
CapEx (TTM)—
FCF Margin-14800.53%
FCF Yield—
Net Debt-6.04M $
Net Debt/EBITDA0.56
Balance Sheet
Debt/Equity50.63
Current Ratio2.11
Quick Ratio2.02
Book Value/Sh0.2670 USD
Cash/Share0.3270 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1.001:1
Split DateJan 9, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float27.69M
Insiders0.53%
Institutions3.88%
Technical
SMA 500.4790 (-48.8%)
SMA 2000.5130 (-52.2%)
Beta1.19
S&P 52W Chg20.80%
Avg Vol (30d)8.19K
Avg Vol (10d)8.43K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—